Background: Human parechovirus (HPeV) and human non-polio enterovirus (EV) are important causes of fever without source (FWS) in young infants. Their prevalence and clinical characteristics are largely unknown in Asian countries. This study was conducted to elucidate the epidemiology and clinical characteristics of HPeV and EV infection in febrile young infants in Japan.
Fever without source (FWS) in neonates-young infants up to 3 months of age is a potentially life-threatening illness because the risk of severe bacterial infection (SBI) at this age is higher than that in older children. 1 Today, the epidemiology of FWS during early infancy has changed because of intrapartum antibiotic prophylaxis for group B streptococcus and the introduction of Haemophilus influenzae type b and pneumococcal vaccination. [2] [3] [4] During the past decade, detection of various viruses has improved by virtue of the development of new molecular techniques and the availability of monoclonal antibodies for many viral species. Furthermore, the FWS etiology during early infancy is being gradually elucidated.
Human parechovirus (HPeV) and human non-polio enterovirus (EV) are important causes of viral infection and meningitis in neonates and young infants. The clinical spectrum of HPeV and EV infections varies from fever to severe systemic disease, including sepsis and meningoencephalitis, which might engender severe neuropsychological sequelae. 5 Several studies have specifically examined HPeV and EV prevalence in European countries and the USA, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] but their prevalence and clinical characteristics remain largely unknown in Asian countries.
This study was conducted to investigate the prevalence of HPeV-and EV-associated infection in a cohort of unselected pediatric patients aged <3 months old admitted with suspicion of infection to a single hospital in Japan. Cases of HPeV and EV infection were identified in non-SBI febrile infants and the clinical features compared.
Methods

Patients
From February 2010 to August 2015, we conducted a prospective study of febrile children aged <3 months with suspected viral infection at Tokyo Women's Medical University Yachiyo Medical Center. This facility is a core hospital in one of nine medical districts in Chiba prefecture, Japan, and 115 000 children reside in this district. We therefore consider that these data reflect a distribution of the causal virus of FWS throughout this district. The Ethics Committee of Tokyo Women's Medical University approved this study (no. 3698).
Criteria for inclusion were neonates and young infants aged <3 months of age with FWS, defined as body temperature ≥38.0°C (100.4°F), with no identified source of infection after careful history taking and thorough physical examination. Body temperature was measured using an axillary thermometer. Neonates born at the present hospital and admitted to the neonatal intensive care unit were excluded. We excluded patients diagnosed with respiratory infection on chest X-ray or rapid antigen tests such as those for respiratory syncytial virus, human metapneumovirus, influenzavirus, and adenovirus. To survey respiratory viruses, we did not use polymerase chain reaction (PCR) or more advanced approaches. We excluded patients with bacterial infection, including bacterial meningitis, bacteremia, urinary tract infection, and soft-tissue infection.
From February 2010 through August 2015, 56 children were examined for this study. We compiled the following clinical information from medical records: patient background, vital signs on admission, symptoms and physical examinations, laboratory data, treatment, clinical course, and prognosis. We assessed laboratory data during the initial visit and at the time of discharge, and determined the maximum and minimums in this period. The criteria for discharge were based on general pediatrician decision with regard to general condition, activity, appetite, and laboratory data. Pediatric intensive care unit (PICU) admission was decided by pediatric intensivists according to consciousness disturbance, respiratory failure, cardiac failure, shock, or organ failure.
Virus detection and typing
From 56 patients, we obtained 53 stool, 44 throat swab, and 20 cerebrospinal fluid (CSF) samples on admission. They were stored at À80°C until nucleic acid extraction. Nucleic acid was extracted using a High Pure Viral RNA kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer instructions. Conventional reverse transcription-PCR (RT-PCR) was then performed using previously described methods with slight modifications. 24, 25 For HPeV detection, a superscript one-step RT-PCR system (Invitrogen, Carlsbad, CA, USA) was used for reverse transcription and first-round PCR with virus-specific primers according to the manufacturer's instructions. First-round PCR was performed using 5 0 untranslated region EV primers (5 0 -CCCTGAATGCGGCTAAT-3 0 , nt 452-468; 5 0 -ATTGTCA CCATAAGCAGCC-3 0 , nt-597-579). 24 To detect all three known HPeV serotypes, new primers were designed just outside the viral protein (VP)1 region, amplifying the complete VP1 region (VP1-parEchoF1, CCAAAATTCRTGGGGT TC; VP1-parEchoR1, AAACCYCTRTCTAAATAWGC). 24 The HPeV VP1 amplicons were gel purified using the Wizardâ SV Gel and PCR Clean-Up System (Promega, Fitchburg, WI, USA). Direct sequencing was then conducted using the ABI PRISM Big Dye Terminator cycle sequencing kit (Applied Biosystems, Waltham, MA, USA) on an ABI Genetic Analyzer 3130 (Applied Biosystems). We performed genotyping by BLASTâ search (NCBI) to confirm the analyzed sequences as derived from HPeV.
Identification of EV serotypes was performed using the CODEHOP PCR method. 25 RNA was reverse-transcripted and first-round PCR performed, 25 followed by second nested PCR using first-round products. Primer sets for the first round and second nested PCR are described in a previous report. 25 The reaction products were purified and sequenced using a sequencing kit (ABI PRISM Big Dye Terminator cycle; Applied Biosystems) on a genetic analyzer (ABI, 3130; Applied Biosystems).
Statistical analysis
Statistical analysis was conducted with R (R Foundation for Statistical Computing, Vienna, Austria). Fisher's exact test was used to compare nominal variable groups. Mann-Whitney U-test was used to compare continuous variable groups. P < 0.05 was defined as significant.
Results
Viral epidemiology
In 31 patients (55.4%), we detected at least one virus (Table 1 ). In 28 patients (50.0%), we detected a single virus alone. Eleven cases of HPeV (19.6%), nine of Coxsackie virus (16.1%), four of echovirus (7.1%), two of rhinovirus (3.6%), and two of other EV (3.6%) were identified. Furthermore, in two patients (3.6%), we detected two coexisting viruses: Coxsackie virus-B and EV (serotype unknown) in one, and echovirus 13 and 25 in the other. In the former patient, we detected Coxsackie virus-B in the throat swab sample and EV in the stool sample. We could not read the sequence completely because the stool sample had a low amount of DNA. In the 11 HPeV patients, two of two CSF specimens, 11 of 11 stool specimens, and eight of 10 throat specimens were positive. In 10 of 11 HPeV patients, HPeV type 3 was confirmed on genotyping. In the other HPeV patient, we were unable to ascertain the genotype. In the 17 EV patients, nine of 11 CSF specimens, 16 of 17 stool specimens, and 13 of 15 throat specimens were positive.
Patient background
Median patient age was 35 days (IQR, 22-65 days). None had a basic disease. The rate of exclusive breast-feeding in the HPeV group was significantly higher than in the EV group (81.8% vs 35.3%; P = 0.024, Table 2 ). The rate of sick contact in the HPeV group was significantly lower than in the EV group (36.4% vs 88.2%; P = 0.010). No other significant differences were noted in patient background.
Age distribution
Age distribution according to virus infection is given in Table 2 , Fig. 1a . Most infants with HPeV were younger than 2 months. Only one patient was older than 2 months in the HPeV group. Regarding the other viruses, no difference was apparent in the prevalence between age groups. A tendency was noted for the median age in the HPeV group to be lower than that in the EV group, but this was not significantly different (32 vs 48 days; P = 0.066).
Seasonal distribution
The seasonal distribution of the respective viruses is shown in Figure 1b . Many patients were admitted during July-September. During January-May there were a few patients, but no viruses were detected. HPeV cases peaked in July and occurred in July-September. EV peaked in August and September and was detected over a longer term than HPeV. The seasonal characteristics are similar to those in recent studies.
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Physical examination
Physical examination results and symptoms are listed in Table 2 . In the HPeV group, grunting was significantly more frequent than in the EV group (63.6% vs 11.8%; P = 0.01). No other physical findings were significantly different between the two groups. In the HPeV group, significantly more patients met systemic inflammatory response syndrome (SIRS) criteria 26 than in the EV group (90.9% vs 52.9%; P = 0.049).
Laboratory data
Laboratory data are listed in Table 3 . In the HPeV group, median minimum WBC (5.18 vs 8.70 9 10 3 /lL; P = 0.008) and platelets (21.4 vs 34.5 9 10 4 /lL; P = 0.01) were significantly lower than in the EV group. Furthermore, in the HPeV group, median maximum aspartate aminotransferase (109 vs 39.5 IU/L; P = 0.008) and lactate dehydrogenase (638 vs 325 IU/L; P = 0.001) were significantly higher than in the EV group. Significant differences in CSF pleocytosis were also noted between the HPeV and EV groups (1.6 vs 8.0/lL; P = 0.009). Furthermore, CSF glucose concentration was also significantly higher in the HPeV group than in the EV group (68.5 vs 51 mg/dL; P = 0.002).
Clinical course
Clinical course is given in Table 4 . In the HPeV group, 10 patients were treated with antibiotics (90.9%), five with oxygen (45.5%), and five with PICU admission (45.5%). No significant difference was noted in the rates of these treatments between the HPeV and EV groups. There was a tendency for median fever duration in the HPeV group to be longer than that in the EV group, but this was not significantly different (4 vs 2; P = 0.14). Median hospital stay was significantly longer in the HPeV group than in the EV group (7 vs 5 days; P = 0.025). In this study, all patients were discharged with full recovery. None had sequelae. CRT, capillary refilling time; EV, human non-polio enterovirus; HPeV, human parechovirus; SIRS, systemic inflammatory response syndrome.
Discussion
In the present study the viral epidemiology of febrile infants aged <3 months near Tokyo, Japan was clarified ( Table 1) . The prevalences of HPeV and EV of 19.6% and 30.4%, respectively, noted in the present study were similar to the 10.7% and 38.1% found in a recent Spanish study of infants up to 1 month of age using CSF, sera and throat swabs. 8 Few reports have assessed the prevalence in Asia. [27] [28] [29] [30] [31] [32] In the present study, most HPeV cases occurred in infants up to 2 months of age. In contrast, EV was identified in infants <3 months of age (Fig. 1a ). Recent reports have described similar results. 14, 17, 33, 34 Some studies noted that this could be due to the differences in the role of transitional antibodies 24, 35 or in the structure of the VP1 region 36 between these viruses. It remains unclear, however, why HPeV would infect younger infants.
The proportion of exclusive breast-feeding was also significantly higher in the HPeV group than in the EV group in the present study (Table 2) . Sadeharju et al. reported that maternal antibodies in breast milk protect children from EV infections, 37 but this has not been investigated in HPeV infection. It would be important to investigate maternal antibodies for HPeV in breast milk.
In the current study, grunting was more frequent, and more patients met the SIRS criteria in the HPeV group than in the EV group (Table 2) . Also, leukopenia, thrombopenia, and elevated deviation enzyme were observed more frequently in the HPeV than in the EV group (Table 3) . Clinical signs such as grunt and laboratory data might reflect the severity of HPeV infection. Along with these results, hospital stay was longer in the HPeV than in the EV group. In contrast, in the EV group, pleocytosis and low glucose were observed in the CSF compared with the HPeV group (Table 3) . Higher CSF protein and pleocytosis have also been reported in EV compared with HPeV infection. 8, 17, 18 The present results should be regarded in the light of some major limitations. First, the small number of cases is the major limitation. No patient had sequelae in the present study and we cannot clarify the overall understanding of the severity of these virus infections. Accumulation of more cases is needed to facilitate discussion of the severity and characteristics of these virus infections. Second, we detected viruses on PCR, not only of sterile samples (e.g. serum, CSF) but also of samples that had potential contamination (e.g. stool, throat swab). At least two of these samples were positive in nine of 11 HPeV patients, and in 15 of 17 EV patients, but the detected viruses were not always the causal viruses.
In conclusion, on assessment of throat swab, stool, and CSF samples in febrile infants <3 months of age, 54% were positive for HPeV or EV. Differences were found in terms of season, age, and laboratory data, but no one finding was sufficient to distinguish between the two virus infections. In terms of clinical signs such as grunting, SIRS criteria, laboratory data, and hospital stay, there were a higher number of severe cases in the HPeV group than in the EV group in the acute phase of infection. Meningitis, however, was more frequent in the EV group. No difference was found in prognosis between the two groups in the present study. Further research needs to be conducted to accumulate more cases, thereby facilitating a comprehensive picture of these virus infections.
